ARTICLE | Distillery Therapeutics
Therapeutics: Kallikrein-related peptidase 5 (KLK5); KLK7; KLK14; suppression of tumorigenicity 14 (ST14; matriptase)
February 19, 2015 8:00 AM UTC
In vitro and mouse studies have identified coumarin-3-carboxylate-based protease inhibitors that could help treat skin diseases such as Netherton syndrome, which is characterized by high levels of Kal...